The earnings call reflected a challenging quarter for Microbix, marked by significant revenue setbacks with two major clients, leading to the weakest performance in three years. However, the company remains financially stable with promising new product developments and ongoing progress in the Kinlytic project. Despite immediate challenges, the company is poised for future growth, building on strong financials and expanding product lines.

Company Guidance

During the call, Microbix provided guidance on their financial and operational outlook following a challenging third quarter in fiscal 2025. The company reported a net loss owing to significant revenue declines from two major clients, which impacted their ability to cover a $5 million to $5.5 million breakeven point. Despite this, they noted a 13% year-to-date growth in their QAPs business excluding those clients, and a 34% growth in their antigen business. The company's balance sheet remains strong, boasting a current ratio of 9.73% and a debt-to-equity ratio of 0.3, alongside cash and cash equivalents of $12 million. With access to up to $24 million in capital, they are positioned to withstand a few quarters of losses. Operational efficiencies are being enhanced, with ongoing investments in R&D and capabilities like synthetic biology. The company is optimistic about future growth, aiming to restore margins by boosting sales by a couple of million per quarter and leveraging new products like QUANTDx. They are also advancing the Kinlytic project, anticipating a 2027 launch with no clinical failure expected. Despite the setbacks, Microbix is committed to expanding their client base and product offerings to drive future growth.

Double-Digit Growth in QAPs and Antigen Business

Excluding two major clients who slowed down, the company saw a 13% growth in its QAPs business and 34% in its antigen business.

Financial Stability

The company maintains a strong balance sheet with a current ratio of 9.73%, a debt-to-equity ratio of 0.3, and cash equivalents of $12 million, allowing access to up to $24 million of capital if needed.

New Product Developments

The company announced a new QUANTDx product line, which will sell at higher prices and embed with customers earlier in assay development.

Kinlytic Progress

Kinlytic's development is on track for a 2027 launch with Sequel funding the commercialization, providing a stable future revenue stream.

Microbix Biosystms (TSE:MBX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:MBX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Dec 18, 2025	2025 (Q4)	- / -	0.003	―	―	―
Aug 14, 2025	2025 (Q3)	- / -0.01	0.002	-700.00% (-0.01)	―	―
May 15, 2025	2025 (Q2)	- / 0.00	0.003	―	―	―
Feb 13, 2025	2025 (Q1)	- / <0.01	0.018	-66.67% (-0.01)	―	―
Dec 19, 2024	2024 (Q4)	- / <0.01	0.014	-78.57% (-0.01)	―	―
Aug 14, 2024	2024 (Q3)	- / <0.01	-0.006	133.33% (<+0.01)	―	―
May 15, 2024	2024 (Q2)	- / <0.01	0	―	―	―
Feb 14, 2024	2024 (Q1)	- / 0.02	-0.009	300.00% (+0.03)	―	―
Dec 21, 2023	2023 (Q4)	>-0.01 / 0.01	-0.009	255.56% (+0.02)	―	―
Aug 10, 2023	2023 (Q3)	0.00 / >-0.01	0.004	-250.00% (-0.01)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:MBX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	C$0.28	C$0.24	-14.29%
May 15, 2025	C$0.36	C$0.34	-5.56%
Feb 13, 2025	C$0.48	C$0.48	0.00%
Dec 19, 2024	C$0.36	C$0.37	+2.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Microbix Biosystms J (TSE:MBX) report earnings?

Microbix Biosystms J (TSE:MBX) is schdueled to report earning on Dec 18, 2025, TBA (Confirmed).

What is Microbix Biosystms J (TSE:MBX) earnings time?

Microbix Biosystms J (TSE:MBX) earnings time is at Dec 18, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:MBX EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing